AstraZeneca Pharma India reported a robust performance in the quarter ended June 30, 2025, with revenue from operations rising to Rs 526.3 crore, a sharp increase from Rs 387.5 crore in the same period last year. Total income stood at Rs 537.5 crore, compared to Rs 395.8 crore in Q1 FY25.
Profit and Margins:
Profit before tax came in at Rs 74.7 crore, compared to a loss of Rs 15.1 crore in the year-ago quarter. Net profit stood at Rs 55.8 crore, a turnaround from a loss of Rs 11.7 crore in Q1 FY25.
Expense Trends:
Total expenses for the quarter were Rs 462.4 crore versus Rs 353.4 crore in Q1 FY25. Purchase of stock-in-trade rose to Rs 417.5 crore from Rs 240.3 crore a year ago, while changes in inventory reflected a negative Rs 131.6 crore due to stock adjustments.
Comparative Highlights:
-
Revenue from operations: Rs 526.3 crore vs Rs 387.5 crore (YoY up 35.8%)
-
Total income: Rs 537.5 crore vs Rs 395.8 crore
-
Net profit: Rs 55.8 crore vs loss of Rs 11.7 crore
-
EBITDA growth: Strong improvement due to higher sales volumes and better cost management.
